장마감
로그인 회원가입
AMPH
AMPH
Amphastar Pharmaceuticals Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$19.18
+0.46 ▲ +2.46%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$19.18
+0.00 +0.00%

앰파스트팜즈(AMPH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$846M
스몰캡
P/E
11.5
저평가 구간
배당수익률
없음
52주 위치
17%
저점 +15% · 고점 -39%
애널리스트
보유
B-
Fundamental health
vs. Drug Manufacturers - Specialty & Generic 소형주
수익성 ⓘ
Top 22%
성장 ⓘ
Top 47%
밸류에이션 ⓘ
Top 73%
재무 안정 ⓘ
Top 26%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 10원. Over the past 5년, it usually traded around 16원. One of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ RUTP/E ⓘ 11.52EPS (ttm) ⓘ 1.66Insider Own ⓘ 26.02%Shs Outstand ⓘ 44.6MPerf Week ⓘ -2.29%
Market Cap ⓘ 0.85BForward P/E ⓘ 6.39EPS next Y ⓘ 16.27%Insider Trans ⓘ -Shs Float ⓘ 32.6MPerf Month ⓘ -8.84%
Enterprise Value ⓘ 1.24BPEG ⓘ 16.39EPS next Q ⓘ 0.62Inst Own ⓘ 73.56%Short Float ⓘ 12.8%Perf Quarter ⓘ -10.42%
Income ⓘ 0.08BP/S ⓘ 1.17EPS this Y ⓘ -20.61%Inst Trans ⓘ -3.17%Short Ratio ⓘ 6.83Perf Half Y ⓘ -26%
Sales ⓘ 0.72BP/B ⓘ 1.11EPS next 5Y ⓘ 0.39%ROA ⓘ 4.84%Short Interest ⓘ 4.17MPerf YTD ⓘ -28.38%
Book/sh ⓘ 17.33P/C ⓘ 2.87EPS past 3/5Y ⓘ 5.29% 134.65%ROE ⓘ 10.39%52W High ⓘ -38.65% ($31.26)Perf Year ⓘ -14.26%
Cash/sh ⓘ 6.68P/FCF ⓘ 6.26Sales past 3/5Y ⓘ 12.99% 15.53%ROIC ⓘ 5.47%52W Low ⓘ 15.23% ($16.65)Perf 3Y ⓘ -68.36%
Dividend Est. ⓘ -EV/EBITDA ⓘ 6.83EPS Y/Y TTM ⓘ -41.7%Gross Margin ⓘ 45.23%Volatility(W/M) ⓘ 2.99% 4.08%Perf 5Y ⓘ -7.74%
Dividend TTM ⓘ -EV/Sales ⓘ 1.72Sales Y/Y TTM ⓘ -1.39%Oper. Margin ⓘ 16.2%ATR (14) ⓘ 0.78Perf 10Y ⓘ 15.75%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.82EPS Q/Q ⓘ -72.73%Profit Margin ⓘ 11%RSI (14) ⓘ 47.39Recom ⓘ 3.14
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.85Sales Q/Q ⓘ 0.38%SMA20 ⓘ -1.47% ($19.47)Beta ⓘ 0.9Target Price ⓘ $22
Payout ⓘ -Debt/Eq ⓘ 0.89Earnings ⓘ 2026/5/7SMA50 ⓘ -0.39% ($19.26)Rel Volume ⓘ 0.47Prev Close ⓘ $18.72
Employees ⓘ 1976LT Debt/Eq ⓘ 0.87EPS/Sales Surpr. ⓘ -40.43% -1.32%SMA200 ⓘ -16.74% ($23.04)Avg Volume(3M) ⓘ 0.61MPrice ⓘ $19.18
IPO ⓘ 2014/6/25Option/Short ⓘ Yes/YesTrades ⓘ 6197Volume ⓘ 285,916Change ⓘ 2.46%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $171M (YoY 0%) · 순이익 $6M (YoY -75%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Amphastar Pharmaceuticals Inc (AMPH) Investment Analysis

What kind of company is Amphastar Pharmaceuticals Inc?

앰파스트팜즈(AMPH) 가치주
Healthcare · Drug Manufacturers - Specialty & Generic
Healthcare Stocks

Ampastar Pharmaceutical Industries is a U.S. specialty and generic pharmaceutical company focused on injectable and inhaled products. It trades under the ticker AMPH. The company directly develops and manufactures products including the glucagon nasal powder BAQSIMI, the generic inhaler Primatene Mist, and injectable medications for emergency and chronic conditions such as epinephrine and lidocaine. Through a vertically integrated production system that spans from raw materials to finished products, it secures both quality and cost competitiveness at the same time.

Learn more about Amphastar Pharmaceuticals Inc →
Market Cap
$0.8B
Approx. KRW 1.2 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2780
Employees1,976people
IPO2014/06/25
Current Price$19.18 ≈ 26,277원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS -40.4% 매출 -1.3%
🔔 Earnings release 2026년 2월 26일 (목) · 장 마감 후 EPS -19.1% 매출 -3.0%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
16.2%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 8.8% · Top 19%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
11.0%
✓ 우수
My positionTop 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median -4.6% · Top 2%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
45.2%
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 Median 57.7% · Bottom 31%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
10.4%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -37.5% · Top 13%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
4.8%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -21.8% · Top 14%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
5.5%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 소형주 Median -25.0% · Top 15%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.89
✓ Average
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 0.36
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.85
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.82
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$22.00
현재가 대비 +14.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
6.39배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
16.39
고평가
💡 PEG > 2 — 성장 대비 비싼 편
내년 EPS 예상 성장률
+16.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+0.4%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-30.5%
평균 서프라이즈
2026.05.07
하회
실적 $0.42 · 예상 $0.71 -40.5%
2026.02.26
하회
실적 $0.73 · 예상 $0.92 -20.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-20.6%
부진
My positionBottom 25%
Low range Average High range
가치주 소형주 Median 4.4% · Bottom 20%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+16.3%
양호
My positionMid-range
Low range Average High range
가치주 소형주 Median 8.6% · Top 34%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+0.4%
평균
My positionMid-range
Low range Average High range
가치주 소형주 Median 3.7% · Bottom 39%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+5.3%
평균
My positionMid-range
Low range Average High range
가치주 소형주 Median 7.7% · Bottom 45%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+134.7%
우수
My positionTop 5%
Low range Average High range
가치주 소형주 Median 10.6% · Top tier
Past 5-Year Revenue
How much revenue grew over the past 5 years
+15.5%
양호
My positionMid-range
Low range Average High range
가치주 소형주 Median 12.0% · Top 36%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+0.4%
평균
My positionMid-range
Low range Average High range
가치주 소형주 Median 4.2% · Bottom 35%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -76%p below the market
AMPH -7.7% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-76.1%p
Significantly behind the market
vs Health Care (XLV)
-32.2%p
Significantly behind the sector average
1-year basis
vs S&P 500
-30.3%p
Significantly behind the market
vs Health Care (XLV)
-34.0%p
Significantly behind the sector average
Rank among peers
5-year return Upper-Mid (37%) Based on 25 peers
1-year return Lower-Mid (lower 41%) Based on 28 peers
Current position within 52-week range
Low (-15.2%p) High (-38.6%p)
Current price is 15.2% above the 52-week low and 38.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-42.3%
Annualized volatility
67.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $19.18 below the midline ($19.47). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.163 < Signal -0.105 in negative zone + Hist negative (-0.057). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 47.4 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 39.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
11.52x
✓ Very cheap
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic median 20.36x · Top 12% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
6.39x
✓ Very cheap
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 10.48x · Top 23% — relatively cheap within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.11x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.17x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 1.56x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
6.83x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.45x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
6.26x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic 소형주 median 9.25x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$22.00 vs. current price +14.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership backdrop is unfavorable
Institutional net selling -3.2% · Short interest elevated 12.8% · Short interest up +1.7pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-3.2%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 73.6%
Adequate institutional weight
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 26.0%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 0.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
12.8%
Somewhat high
Healthcare 소형주 Median 11.2%
Past 90 days 📈 +1.7%p increase
Short interest days to cover
6.8 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 44.6M주
Float (tradable shares) 32.6M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding AMPH

ETFs with the highest weightings · 10 total shown
PJP
PJP
Invesco Pharmaceuticals ETF
2.33%
$454M
XPH
XPH
State Street SPDR S&P Pharmaceuticals ETF
1.45%
$475M
ACVT
ACVT
Advent Convertible Bond ETF
1.22%
$32M
PILL
PILL
Direxion Daily Pharmaceutical & Medical Bull 3X ETF
1.13%
$21M
DEEP
DEEP
Acquirers Small and Micro Deep Value ETF
0.71%
$27M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
AMPH AMPH This Stock
$845.7M11.5 ▲1.1 ▲10.39% ▲- +2.5%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
암파스타 파마슈티컬스(AMPH) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
암파스타 파마슈티컬스(티커 AMPH)는 BAQSIMI·Primatene 등 주사·흡입 의약품 중심의 미국 특수·제네릭 제약사로, 수직 통합 생산을 기반으로 한 안정적 매출과 신제품 파이프라인이 주가·실적 전망의 핵심으로 평가됩니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 앰파스트팜즈(AMPH)?

앰파스트팜즈(AMPH) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of AMPH?

The market cap of AMPH is approximately $846M, ranking 2,780 within its sector.

What is the P/E ratio of AMPH?

AMPH has a P/E ratio of approximately 11.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for AMPH?

AMPH has recorded a 52-week high of $31.26 and a low of $16.65.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.